Vimarsana
Biggest News Aggregation in the World

Page 2 - Viveve Systems News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Viveve Systems. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Viveve Systems Today - Breaking & Trending Today

Viveve to Participate in H.C. Wainwright 24th Annual Global Investment Conference - Vimarsana News

Viveve to Participate in H.C. Wainwright 24th Annual Global Investment Conference

Press release content from Accesswire. The AP news staff was not involved in its creation.

Source: apnews.com
Viveve Medical, Inc.: Viveve Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Vimarsana News

Viveve Medical, Inc.: Viveve Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tipsPURSUIT clinical trial follow-up visit completion anticipated by year endConference call to be hosted by Company at

Viveve Medical, Inc.: Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan - Vimarsana News

Viveve Medical, Inc.: Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan

ENGLEWOOD, CO / ACCESSWIRE / July 12, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced

Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan - Vimarsana News

Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan

Press release content from Accesswire. The AP news staff was not involved in its creation.

Source: apnews.com
Viveve Medical, Inc.: Viveve Reports Full Year 2021 Financial Results and Provides Corporate Update - Vimarsana News

Viveve Medical, Inc.: Viveve Reports Full Year 2021 Financial Results and Provides Corporate Update

Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growthEnrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post treatment